{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:02:20Z","timestamp":1791331340391,"version":"4.3.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01263-3","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T14:02:53Z","timestamp":1743256973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-3424","authenticated-orcid":false,"given":"Vinod","family":"Pullarkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-8266","authenticated-orcid":false,"given":"Keith W.","family":"Pratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"Recher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-0261","authenticated-orcid":false,"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ho","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-7265","authenticated-orcid":false,"given":"Gunnar","family":"Juliusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Selleslag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Ridgeway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalaja","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovita","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"1263_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1263_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/genes11070749","volume":"11","author":"A Higgins","year":"2020","unstructured":"Higgins A, Shah MV. Genetic and genomic landscape of secondary and therapy-related acute myeloid leukemia. Genes. 2020;11:749.","journal-title":"Genes"},{"key":"1263_CR3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","volume":"366","author":"MJ Walter","year":"2012","unstructured":"Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090\u20138.","journal-title":"N Engl J Med"},{"key":"1263_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0296-3","volume":"10","author":"AK Schmaelter","year":"2020","unstructured":"Schmaelter AK, Labopin M, Soci\u00e9 G, It\u00e4l\u00e4-Remes M, Blaise D, Yakoub-Agha I, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10:26.","journal-title":"Blood Cancer J"},{"key":"1263_CR5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","volume":"6","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2022","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Meg\u00edas-Vericat JE, Serrano J, Mart\u00ednez-S\u00e1nchez P, Rodr\u00edguez-Arbol\u00ed E, Gil C, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6:1278\u201395.","journal-title":"Blood Adv"},{"key":"1263_CR6","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"1263_CR7","unstructured":"VENCLEXTA\u00ae (venetoclax tablets), for oral use [prescribing information]. North Chicago, IL: AbbVie, Inc.; 2022."},{"key":"1263_CR8","doi-asserted-by":"publisher","first-page":"2196482","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"MZ Mohamed Jiffry","year":"2023","unstructured":"Mohamed Jiffry MZ, Kloss R, Ahmed-khan M, Carmona-Pires F, Okam N, Weeraddana P, et al. A review of treatment options employed in relapsed\/refractory AML. Hematology. 2023;28:2196482.","journal-title":"Hematology"},{"key":"1263_CR9","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3390\/cancers14082025","volume":"14","author":"S Garciaz","year":"2022","unstructured":"Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, et al. Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers. 2022;14:2025.","journal-title":"Cancers"},{"key":"1263_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1263_CR11","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1200\/JCO.2021.39.15_suppl.7011","volume":"39","author":"V Pullarkat","year":"2021","unstructured":"Pullarkat V, Pratz K, Dohner H, Recher C, Thirman MJ, Dinardo CD, et al. Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic\/myeloproliferative neoplasms. J Clin Oncol. 2021;39:7011.","journal-title":"J Clin Oncol"},{"key":"1263_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"1263_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"1263_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615\u201324.","journal-title":"Am J Hematol"},{"key":"1263_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01263-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T14:02:55Z","timestamp":1743256975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01263-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1263"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01263-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VP reports advisory board fees\/consultancy\/speaker\u2019s bureau from AbbVie, Genentech, Pfizer, Jazz, Novartis, Rigel, Sobi, Sanofi, and Amgen. KWP reports grant support and advisory board fees from AbbVie; grant support from Agios, Daiichi-Sankyo, and Millennium; and advisory board fees from Astellas. HD reports advisory role for AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, BMS, Celgene, Gilead, Janssen, Jazz, Novartis, Servier, Stemline, and Syndax and research funding from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Novartis, and Pfizer. CR reports a consulting or advisory role with AbbVie, Amgen, Astellas, BMS, Boehringer, Jazz Pharmaceuticals, and Servier; research funding from AbbVie, Amgen, Astellas, BMS, Iqvia, and Jazz Pharmaceuticals; and support for attending meetings and\/or travel from AbbVie, Novartis, and Servier. MJT reports grant support, consulting fees, and advisory board fees from AbbVie, Janssen, Pharmacyclics, Celgene, AstraZeneca, and Roche\/Genentech and research funding from AbbVie, Gilead Sciences, Merck, Janssen, Pharmacyclics, Syndax, and TG Therapeutics. CDD reports research support (to institution) from AbbVie, Agios, Astex, BeiGene, BMS, Cleave, Foghorn, Forma\/Rigel, Immune-Onc, Loxo, and Servier and consultancies\/advisory board memberships for AbbVie, Astellas, BMS, Genentech, Genmab, Gilead, GSK, Immunogen, Jazz, Novartis, Notable Labs, Rigel, and Servier. PF reports consulting fees from BMS, AbbVie, Janssen, Jazz, and Novartis and research funding (as GFM chair) from AbbVie, Jazz, BMS, Janssen, and Novartis. ACS reports consultant\/advisory board\/research support from, AbbVie, Agios, Amgen, Astellas, Celgene\/BMS, GlycoMimetics, Jazz, Novartis, Phebra, Pfizer, and Teva. AHW reports serving on advisory boards for Novartis, Astra Zeneca, Astellas, GSK, Janssen, Jazz, Amgen, Roche, Pfizer, AbbVie, Servier, Gilead, BMS and BeiGene; consultation for AbbVie, Servier, Novartis, Shoreline, and Aculeus; research funding to the institution from Novartis, AbbVie, Servier, BMS, Janssen, Syndax, Astex, Astra Zeneca, and Amgen; serving on speaker\u2019s bureaus for AbbVie, Novartis, BMS, Servier, and Astellas; and employment by the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to the development of venetoclax. Current and past employees of WEHI may be eligible for financial benefits related to these payments. AHW receives such a financial benefit. AP reports a consulting or advisory role with AbbVie, Astellas, BMS, Jazz Pharmaceuticals, and Servier; research funding from AbbVie, Astellas, BMS, and Jazz Pharmaceuticals; and support for attending meetings and\/or travel from AbbVie, Novartis, and Servier. J-HJ reports being an investigator in an AbbVie-funded trial. GJ reports advisory roles for AbbVie, Astellas, Celgene, and Novartis; and research collaboration with Amgen, Jazz Pharma, and Novartis. YM reports honoraria from Novartis, Celgene, Sumitomo Pharma, Nippon Shinyaku, Chugai, Otsuka, Astellas, and Kyowa-Kirin, and research funding from Chugai, and Sumitomo Pharma. DS reports advisory roles for AbbVie, Sunesis, Janssen, Novartis, Celgene, Otsuka, MSD, Daiichi-Sankyo, Pfizer, Takeda, Astellas, and Teva. MA reports advisory role for Syndax pharmaceuticals. CL reports employment by AbbVie and may hold stock or stock options. JAR reports employment by AbbVie and may hold stock or stock options. JP reports consulting fees as an employee of AbbVie and may hold stock or stock options. JS reports employment by AbbVie and may hold stock or stock options. MK reports advisory roles and consulting fees from AbbVie, Genentech, F. Hoffmann La-Roche, Stemline Therapeutics, Forty-Seven, Auxenion, Boehringer, and Dark Blue Therapeutics, grant support from AbbVie, Allogene, Astra Zeneca, Genentech, Gilead, ImmunoGen, MEI Pharma, Precision Bio, Rafael Pharmaceutical, Sanofi, Stemline-Menarini, Legend, Redona, Sellas, and Vincerx; royalties and stock options from Reata Pharmaceutical Inc.; patent US 7,795,305 B2 on CDDO-compounds and combination therapies, licensed to Reata Pharmaceutical; and patents with Novartis, Reata Pharm, and Eli Lilly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}